Fusion Antibodies and Isca Diagnostics announce collaboration on antibodies.

Queens University Belfast spin-out Fusion Antibodies has announced plans to collaborate with Isca Diagnostics, commercialising technology from the University of Exeter, on developing antibodies.

Specifically, the two life science firms will be working on the diagnosis and therapy of aspergillosis; a variety of diseases caused by fungal infection. Most humans inhale spores from the Aspergillus genus every day without cause for concern. However, individuals who have become immunocompromised, through drugs or disease, can become susceptible.

The condition can lead to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?